|
1
|
Zhang B, Chikuma S, Hori S, Fagarasan S
and Honjo T: Nonoverlapping roles of PD-1 and FoxP3 in maintaining
immune tolerance in a novel autoimmune pancreatitis mouse model.
Proc Natl Acad Sci USA. 113:pp. 8490–8495. 2016; View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang J, Okazaki IM, Yoshida T, Chikuma S,
Kato Y, Nakaki F, Hiai H, Honjo T and Okazaki T: PD-1 deficiency
results in the development of fatal myocarditis in MRL mice. Int
Immunol. 22:443–452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heeren AM, Koster BD, Samuels S, Ferns DM,
Chondronasiou D, Kenter GG, Jordanova ES and de Gruijl TD: High and
interrelated rates of PD-L1+CD14+
antigen-presenting cells and regulatory T cells mark the
microenvironment of metastatic lymph nodes from patients with
cervical cancer. Cancer Immunol Res. 3:48–58. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yaguchi T and Kawakami Y: Cancer-induced
heterogeneous immunosuppressive tumor microenvironments and their
personalized modulation. Int Immunol. 28:393–399. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fourcade J, Sun Z, Pagliano O, Chauvin JM,
Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S,
et al: PD-1 and Tim-3 regulate the expansion of tumor
antigen-specific CD8+ T cells induced by melanoma
vaccines. Cancer Res. 74:1045–1055. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weber JS, O'Day S, Urba W, Powderly J,
Nichol G, Yellin M, Snively J and Hersh E: Phase I/II study of
ipilimumab for patients with metastatic melanoma. J Clin Oncol.
26:5950–5956. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okazaki T, Chikuma S, Iwai Y, Fagarasan S
and Honjo T: A rheostat for immune responses: The unique properties
of PD-1 and their advantages for clinical application. Nat Immunol.
14:1212–1218. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weber JS, D'Angelo SP, Minor D, Hodi FS,
Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD,
et al: Nivolumab versus chemotherapy in patients with advanced
melanoma who progressed after anti-CTLA-4 treatment (CheckMate
037): A randomised, controlled, open-label, phase 3 trial. Lancet
Oncol. 16:375–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Akiyama Y, Kondou R, Iizuka A, Ohshima K,
Urakami K, Nagashima T, Shimoda Y, Tanabe T, Ohnami S, Ohnami S, et
al: Immune response-associated gene analysis of 1,000 cancer
patients using whole-exome sequencing and gene expression
profiling-Project HOPE. Biomed Res. 37:233–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Urakami K, Shimoda Y, Ohshima K, Nagashima
T, Serizawa M, Tanabe T, Saito J, Usui T, Watanabe Y, Naruoka A, et
al: Next generation sequencing approach for detecting 491 fusion
genes from human cancer. Biomed Res. 37:51–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamaguchi K, Urakami K, Ohshima K,
Mochizuki T, Akiyama Y, Uesaka K, Nakajima T, Takahashi M, Tamai S
and Kusuhara M: Implementation of individualized medicine for
cancer patients by multiomics-based analyses-the Project HOPE-.
Biomed Res. 35:407–412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ohshima K, Hatakeyama K, Nagashima T,
Watanabe Y, Kanto K, Doi Y, Ide T, Shimoda Y, Tanabe T, Ohnami S,
et al: Integrated analysis of gene expression and copy number
identified potential cancer driver genes with
amplification-dependent overexpression in 1,454 solid tumors. Sci
Rep. 7:6412017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: KEYNOTE-001 Investigators: Pembrolizumab for the treatment
of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dahlin AM, Henriksson ML, Van Guelpen B,
Stenling R, Oberg A, Rutegård J and Palmqvist R: Colorectal cancer
prognosis depends on T-cell infiltration and molecular
characteristics of the tumor. Mod Pathol. 24:671–682. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hallett RM, Dvorkin-Gheva A, Bane A and
Hassell JA: A gene signature for predicting outcome in patients
with basal-like breast cancer. Sci Rep. 2:2272012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Munson DJ, Egelston CA, Chiotti KE, Parra
ZE, Bruno TC, Moore BL, Nakano TA, Simons DL, Jimenez G, Yim JH, et
al: Identification of shared TCR sequences from T cells in human
breast cancer using emulsion RT-PCR. Proc Natl Acad Sci USA.
113:pp. 8272–8277. 2016; View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mickley A, Kovaleva O, Kzhyshkowska J and
Gratchev A: Molecular and immunologic markers of kidney
cancer-potential applications in predictive, preventive and
personalized medicine. EPMA J. 6:202015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maglietta A, Maglietta R, Staiano T,
Bertoni R, Ancona N, Marra G and Resta L: The immune landscapes of
polypoid and nonpolypoid precancerous colorectal lesions. PLoS One.
11:e01593732016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee HJ, Lee JJ, Song IH, Park IA, Kang J,
Yu JH, Ahn JH and Gong G: Prognostic and predictive value of
NanoString-based immune-related gene signatures in a neoadjuvant
setting of triple-negative breast cancer: Relationship to
tumor-infiltrating lymphocytes. Breast Cancer Res Treat.
151:619–627. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang LP, Cao J, Zhang J, Wang BY, Hu XC,
Shao ZM, Wang ZH and Ou ZL: The human chemokine receptor CCRL2
suppresses chemotaxis and invasion by blocking CCL2-induced
phosphorylation of p38 MAPK in human breast cancer cells. Med
Oncol. 32:2542015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Callahan MJ, Nagymanyoki Z, Bonome T,
Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu
J, Birrer MJ, et al: Increased HLA-DMB expression in the tumor
epithelium is associated with increased CTL infiltration and
improved prognosis in advanced-stage serous ovarian cancer. Clin
Cancer Res. 14:7667–7673. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Avalle L, Pensa S, Regis G, Novelli F and
Poli V: STAT1 and STAT3 in tumorigenesis: A matter of balance.
JAK-STAT. 1:65–72. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nam KO, Kang WJ, Kwon BS, Kim SJ and Lee
HW: The therapeutic potential of 4–1BB (CD137) in cancer. Curr
Cancer Drug Targets. 5:357–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Taube JM, Young GD, McMiller TL, Chen S,
Salas JT, Pritchard TS, Xu H, Meeker AK, Fan J, Cheadle C, et al:
Differential expression of immune-regulatory genes associated with
PD-L1 display in melanoma: Implications for PD-1 pathway blockade.
Clin Cancer Res. 21:3969–3976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kawakami Y, Yaguchi T, Sumimoto H,
Kudo-Saito C, Tsukamoto N, Iwata-Kajihara T, Nakamura S, Nishio H,
Satomi R, Kobayashi A, et al: Roles of signaling pathways in cancer
cells and immune cells in generation of immunosuppressive
tumor-associated microenvironmentsThe Tumor Immunoenvironment.
Shurin MR, Umansky V and Malyguine A: Springer Science+Buisiness
Media B.V.; Dordrecht, The Netherlands: pp. 307–323. 2013,
View Article : Google Scholar
|
|
30
|
Schabath MB, Welsh EA, Fulp WJ, Chen L,
Teer JK, Thompson ZJ, Engel BE, Xie M, Berglund AE, Creelan BC, et
al: Differential association of STK11 and TP53 with KRAS
mutation-associated gene expression, proliferation and immune
surveillance in lung adenocarcinoma. Oncogene. 35:3209–3216. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Loi S, Dushyanthen S, Beavis PA, Salgado
R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV,
et al: RAS/MAPK activation is associated with reduced
tumor-infiltrating lymphocytes in triple-negative breast cancer:
Therapeutic cooperation between MEK and PD-1/PD-L1 immune
checkpoint inhibitors. Clin Cancer Res. 22:1499–1509. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Frederick DT, Piris A, Cogdill AP, Cooper
ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, et
al: BRAF inhibition is associated with enhanced melanoma antigen
expression and a move favorable tumor microenvironment in patients
with metastatic melanoma. Clin Cancer Res. 19:1225–1231. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wouters MC, Komdeur FL, Workel HH, Klip
HG, Plat A, Kooi NM, Wisman GB, Mourits MJ, Arts HJ, Oonk MH, et
al: Treatment regimen, surgical outcome, and T-cell differentiation
influence prognostic benefit of tumor-infiltrating lymphocytes in
high-grade serous ovarian cancer. Clin Cancer Res. 22:714–724.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hojo S, Koizumi K, Tsuneyama K, Arita Y,
Cui Z, Shinohara K, Minami T, Hashimoto I, Nakayama T, Sakurai H,
et al: High-level expression of chemokine CXCL16 by tumor cells
correlates with a good prognosis and increased tumor-infiltrating
lymphocytes in colorectal cancer. Cancer Res. 67:4725–4731. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao L, Zhu S, Gao Y and Wang Y: Two-gene
expression ratio as predictor for breast cancer treated with
tamoxifen: Evidence from meta-analysis. Tumour Biol. 35:3113–3117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nolan E, Vaillant F, Branstetter D, Pal B,
Giner G, Whitehead L, Lok SW, Mann GB, Rohrbach K, Huang LY, et al
Kathleen Cuningham Foundation Consortium for Research into Familial
Breast Cancer (kConFab), : RANK ligand as a potential target for
breast cancer prevention in BRCA1-mutation carriers. Nat Med.
22:933–939. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheon DJ, Li AJ, Beach JA, Walts AE, Tran
H, Lester J, Karlan BY and Orsulic S: ADAM12 is a prognostic factor
associated with an aggressive molecular subtype of high-grade
serous ovarian carcinoma. Carcinogenesis. 36:739–747. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Duan M, Wang ZC, Wang XY, Shi JY, Yang LX,
Ding ZB, Gao Q, Zhou J and Fan J: TREM-1, an inflammatory
modulator, is expressed in hepatocellular carcinoma cells and
significantly promotes tumor progression. Ann Surg Oncol.
22:3121–3129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mandal R and Chan TA: Personalized
oncology meets immunology: The path toward precision immunotherapy.
Cancer Discov. 6:703–713. 2016. View Article : Google Scholar : PubMed/NCBI
|
